CNSigs: An R Package for the Identification of Copy Number Mutational Signatures

BackgroundCopy number aberrations (CNAs) are gains and losses of large genomic segments present across most cancer types and are a hallmark of cancer genomic alterations. However, the processes underlying CNAs and characteristic patterns of CNAs are poorly understood. Bioinformatic advances have identified underlying single nucleotide variant (SNV) mutational signatures resulting from distinct mutational processes, yet development of algorithms able to uncover similar signatures for CNAs remains less advanced. MethodsUsing segmented data files from DNA sequencing, six copy number features are extracted for signature determination: segment size, breakpoints per 10 megabases, copy number oscillation events, average changepoint size, average copy number, and breakpoints per chromosome arm, along with ploidy. Mixed model approaches and non-negative matrix factorization (NMF) are utilized to derive CNA signatures across cancer types. The full methodology was packaged in a robust R package, termed CNSigs that is publicly available. ResultsTo verify the reproducibility of the signatures, we derived five signatures from two independent breast cancer datasets (total n>3000), demonstrating high accuracy (average cosine similarity = 0.89). Pan-cancer application of CNSigs in the TCGA dataset resulted in derivation of 13 pan-cancer signatures which were significantly associated with disease-specific survival. Benchmarking CNSigs to two other CNA signature approaches within TCGA demonstrated non-overlapping signatures and favorable compute speed for CNSigs. We evaluated n=24 pairs of tumor and circulating tumor DNA (ctDNA) acquired at the same time and demonstrated that CNSigs are detectable and reproducible via ctDNA, with significant association of CNSig11 with metastatic triple-negative breast cancer progression-free survival for taxane but not platinum or capecitabine chemotherapy. CNSigs association with immunophenotype was evaluated in low-grade glioma (LGG) and CNSig 3 was found to be highly prognostic for LGG yet complementary to immune features. ConclusionsThe CNSigs R package allows researchers to easily analyze their own samples to derive copy number signatures and evaluate clinical associations. We demonstrate potential application in ctDNA and association with treatment response. The development of this package allows further investigation of underlying processes that may be responsible for these CNA fingerprints.